Krystal Biotech - KRYS Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $171.00
Forecasted Upside: 9.84%
Number of Analysts: 9
Breakdown:
0 Sell Ratings
0 Hold Ratings
9 Buy Ratings
0 Strong Buy Ratings

^$155.68 As of 04/25/2024 01:00 AM ET

▼ -3.37 (-2.12%)

1 month | 3 months | 12 months

Get New Krystal Biotech Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for KRYS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KRYS

^$171.00

▲ +9.84% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is $171.00, with a high forecast of $204.00 and a low forecast of $118.00. The average price target represents a 9.84% upside from the last price of $155.68.

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Krystal Biotech. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/2/2022

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/31/2023

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/1/2023

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/30/2023

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/28/2023

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/26/2024

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/26/2024

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/25/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/22/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$200.00	Low
4/16/2024	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$178.00 ➝ $204.00	Low
2/27/2024	Guggenheim	Boost Target	Buy ➝ Buy	$130.00 ➝ $175.00	Low
2/27/2024	Citigroup	Boost Target	Buy ➝ Buy	$160.00 ➝ $195.00	Low
2/27/2024	William Blair	Reiterated Rating	Outperform		Low
12/13/2023	Cantor Fitzgerald	Boost Target	Overweight ➝ Overweight	$160.00 ➝ $180.00	Low
11/20/2023	The Goldman Sachs Group	Initiated Coverage	Buy	$160.00	Low
11/7/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$160.00	Low
10/24/2023	Cantor Fitzgerald	Initiated Coverage	Overweight	$100.00	Low
10/12/2023	Citigroup	Initiated Coverage	Buy	$160.00	Low
9/7/2023	Berenberg Bank	Initiated Coverage	Buy	$154.00	Low
8/7/2023	Chardan Capital	Boost Target	Buy ➝ Buy	$148.00 ➝ $153.00	Low
8/7/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$139.00	Low
5/24/2023	Stifel Nicolaus	Boost Target		$102.00 ➝ $145.00	Low
5/22/2023	Guggenheim	Boost Target		$101.00 ➝ $130.00	Low
5/22/2023	Chardan Capital	Boost Target		$133.00 ➝ $148.00	Low
5/22/2023	HC Wainwright	Boost Target		$119.00 ➝ $139.00	Low
5/21/2023	Bank of America	Boost Target		$105.00 ➝ $118.00	Low
4/17/2023	Stifel Nicolaus	Initiated Coverage	Buy	$102.00	Low
3/22/2023	William Blair	Reiterated Rating	Outperform		Low
2/28/2023	Guggenheim	Reiterated Rating	Buy	$101.00	Low
2/28/2023	Chardan Capital	Reiterated Rating	Buy	$133.00	Low
2/28/2023	HC Wainwright	Reiterated Rating	Buy	$119.00	Low
2/28/2023	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$79.00 ➝ $124.00	Low
11/7/2022	Chardan Capital	Boost Target	Buy	$130.00 ➝ $133.00	Low
11/7/2022	HC Wainwright	Boost Target	Buy	$107.00 ➝ $119.00	Low
8/24/2022	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$74.00	Low
8/9/2022	Chardan Capital	Lower Target	Buy	$137.00 ➝ $130.00	Low
5/24/2022	The Goldman Sachs Group	Lower Target	Buy	$91.00 ➝ $78.00	High
3/29/2022	Guggenheim	Lower Target		$114.00 ➝ $101.00	High
3/1/2022	The Goldman Sachs Group	Lower Target	Buy	$125.00 ➝ $93.00	High
2/28/2022	HC Wainwright	Lower Target	Buy	$124.00 ➝ $107.00	Low
1/18/2022	Bank of America	Initiated Coverage	Buy	$110.00	High
11/30/2021	The Goldman Sachs Group	Boost Target	Buy	$85.00 ➝ $125.00	High
11/29/2021	HC Wainwright	Boost Target	Positive ➝ Buy	$103.00 ➝ $124.00	N/A
7/20/2021	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$73.00 ➝ $90.00	Medium
7/2/2021	Jonestrading	Reiterated Rating	Buy	$97.00	Low
7/2/2021	William Blair	Reiterated Rating	Buy		Medium
7/1/2021	Chardan Capital	Reiterated Rating	Buy		Medium
3/1/2021	HC Wainwright	Boost Target	Buy	$84.00 ➝ $103.00	Low
2/9/2021	Jonestrading	Initiated Coverage	Buy	$97.00	Low
1/8/2021	HC Wainwright	Boost Target	Buy	$68.00 ➝ $84.00	Medium
11/11/2020	B. Riley	Reiterated Rating	Buy	$100.00	Low
9/30/2020	B. Riley	Initiated Coverage	Buy		Medium
9/18/2020	B. Riley	Initiated Coverage	Buy	$100.00	High
8/25/2020	Chardan Capital	Reiterated Rating	Buy	$115.00	Low
8/19/2020	Chardan Capital	Boost Target	Buy	$100.00 ➝ $115.00	High
8/10/2020	HC Wainwright	Reiterated Rating	Buy	$68.00	Medium
6/4/2020	Evercore ISI	Initiated Coverage	Outperform	$90.00	High
5/8/2020	Chardan Capital	Reiterated Rating	Buy	$100.00	High
5/4/2020	HC Wainwright	Reiterated Rating	Buy	$68.00	High
5/4/2020	William Blair	Reiterated Rating	Buy		High
3/10/2020	Chardan Capital	Reiterated Rating	Buy	$100.00	High
3/10/2020	HC Wainwright	Boost Target	Buy	$59.00 ➝ $68.00	High
1/30/2020	Chardan Capital	Reiterated Rating	Buy	$90.00	Medium
11/5/2019	Cowen	Reiterated Rating	Buy		Medium
11/4/2019	William Blair	Reiterated Rating	Buy		High
9/26/2019	Guggenheim	Set Target	Buy	$81.00	High
9/24/2019	The Goldman Sachs Group	Initiated Coverage	Neutral	$60.00	High
9/4/2019	William Blair	Reiterated Rating	Buy		Low
9/4/2019	HC Wainwright	Set Target	Buy	$59.00	Low
8/15/2019	Cowen	Reiterated Rating	Buy		Low
8/6/2019	HC Wainwright	Boost Target	Buy ➝ Buy	$56.00 ➝ $59.00	High
6/25/2019	Guggenheim	Boost Target	Buy	$48.00 ➝ $73.00	High
6/24/2019	HC Wainwright	Boost Target	Buy ➝ Buy	$38.00 ➝ $56.00	High
6/24/2019	Chardan Capital	Boost Target	Buy	$57.50 ➝ $75.00	High
6/24/2019	William Blair	Reiterated Rating	Buy		High
5/30/2019	Guggenheim	Initiated Coverage	Buy	$31.57	Medium
5/24/2019	HC Wainwright	Boost Target	Buy ➝ Positive	$32.00 ➝ $38.00	Low
5/6/2019	William Blair	Reiterated Rating	Buy		Low
5/6/2019	Cowen	Reiterated Rating	Buy		High

(Data available from 4/25/2019 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

8 very positive mentions
11 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/28/2023

1 very positive mentions
2 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

10/28/2023

8 very positive mentions
7 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

11/27/2023

7 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/27/2023

8 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/26/2024

12 very positive mentions
13 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/25/2024

18 very positive mentions
19 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

3/26/2024

10 very positive mentions
10 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

4/25/2024

Current Sentiment

Recent Stories by Sentiment

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Today's Range

Now: $155.68

$153.44

$157.71

50 Day Range

MA: $162.61

$108.01

$180.42

52 Week Range

Now: $155.68

$82.09

$189.97

Volume

242,413 shs

Average Volume

366,250 shs

Market Capitalization

$4.44 billion

P/E Ratio

1,946.24

Dividend Yield

N/A

Beta

0.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Krystal Biotech?: The following equities research analysts have issued stock ratings on Krystal Biotech in the last year: Bank of America Co., Berenberg Bank, Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Guggenheim, HC Wainwright, Stifel Nicolaus, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for KRYS.
What is the current price target for Krystal Biotech?: 9 Wall Street analysts have set twelve-month price targets for Krystal Biotech in the last year. Their average twelve-month price target is $171.00, suggesting a possible upside of 9.8%. Stifel Nicolaus has the highest price target set, predicting KRYS will reach $204.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $118.00 for Krystal Biotech in the next year.
View the latest price targets for KRYS.
What is the current consensus analyst rating for Krystal Biotech?: Krystal Biotech currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KRYS will outperform the market and that investors should add to their positions of Krystal Biotech.
View the latest ratings for KRYS.
What other companies compete with Krystal Biotech?: Other companies that are similar to Krystal Biotech include CRISPR Therapeutics, Halozyme Therapeutics, Immunovant, ImmunityBio and Iovance Biotherapeutics. Learn More about companies similar to Krystal Biotech.
How do I contact Krystal Biotech's investor relations team?: Krystal Biotech's physical mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company's listed phone number is (412) 586-5830 and its investor relations email address is [email protected]. The official website for Krystal Biotech is www.krystalbio.com. Learn More about contacing Krystal Biotech investor relations.

Krystal Biotech - KRYS Stock Price Target and Predictions

Analyst Price Target for KRYS

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.68 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Krystal Biotech?

What is the current price target for Krystal Biotech?

What is the current consensus analyst rating for Krystal Biotech?

What other companies compete with Krystal Biotech?

How do I contact Krystal Biotech's investor relations team?